White House advisor Fauci says coronavirus vaccine trial is on target and will be 'ultimate game changer' [CNBC]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: CNBC
The first human trial testing a potential vaccine to prevent COVID-19 is "on track" with public distribution still projected in 12 to 18 months, which would be the "ultimate game changer" in the fight against the pandemic, White House health advisor Dr. Anthony Fauci said Wednesday. U.S. health officials have been fast-tracking work with biotech company Moderna to develop a vaccine to prevent COVID-19. They began their first human trials on a potential vaccine March 16. The trial had to test three different doses of the vaccine, Fauci said, adding that they've already tested the first two doses and are now administering the highest dose to human volunteers to see if there are any adverse reactions to it. "It'll take a few months to get the data to where we'll feel confident to go to the phase two, and then a few months from now we'll be in phase two and I think we're right on target for the year to year and a half," Fauci said at a White House press conference with President Donald Tr
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- U.S. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Market Research: Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]Yahoo! Finance
- Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? [Yahoo! Finance]Yahoo! Finance
- Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $41.00 price target on the stock.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $45.00. They now have an "underweight" rating on the stock.MarketBeat
MRNA
Earnings
- 11/7/24 - Beat
MRNA
Sec Filings
- 12/10/24 - Form 4
- 12/9/24 - Form 144
- 12/6/24 - Form 4
- MRNA's page on the SEC website